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Differences in the blood pressure between arms (inter-arm
difference; IAD) are regularly encountered in assessing people
with hypertension. A pooled analysis of community-based studies
found systolic IADs ≥10mmHg in 11.2% of people with
hypertension, 7.4% with diabetes and 3.6% of a general adult
population [1]. A systolic IAD ≥ 10mmHg is associated with
increased cardiovascular and all-cause mortality, and with
cardiovascular events. We have recently confirmed this in an
individual participant data (IPD) meta-analysis using 10 years of
follow up data from over 50,000 participants pooled from 24
cohorts to establish the INTERPRESS-IPD Collaboration. We derived
and validated prediction models which included systolic IAD as a
risk marker, and confirmed the association of IAD with elevated
risk after adjustment for frequently used cardiovascular risk
prediction scores (ASCVD, Framingham and QRISK2) [2]. This work
was designed to support interpretation of an IAD to stratify
risk and inform management decisions within a primary care
population.
In a linked paper Nolde et al. consider whether IAD could also
be useful for the stratification of higher-risk groups. They
examined the associations of IAD with vascular target organ
damage in 199 patients recruited from a tertiary hypertension
outpatient clinic; carotid-femoral pulse wave velocity (PWV) was
adopted as a surrogate marker of hypertension-mediated vascular
organ damage [3]. In this selected cohort, they were unable to
show a cross-sectional relationship between IAD and PWV. Further
analyses also failed to find an association of IAD with either
absolute blood pressure (BP) levels or BP variability.
PWV provides a quantitative assessment of arterial stiffening
and is a recognised risk marker for cardiovascular events [4]. The
aetiology of an IAD is not clearly established; initially regarded as
subclavian stenosis on the side of the lower reading arm, to date
there has been a paucity of evidence to support such an
association in the absence of substantial (i.e., ≥35mmHg) systolic
BP differences between arms [5]. There is a growing body of
evidence to associate IAD with elevated arterial stiffness
manifested as increased PWV and/or pulse pressure [6, 7]. It
seems likely that IAD is largely, if not fully, mediated by
asymmetries in arterial stiffness, and that this pathophysiology
underlies the independent associations of IAD with cardiovascular
risk. In truth, it is probable that both stenoses and stiffening of
arteries make contributions to the phenomenon of IAD and since
both pathologies share common underlying causes the distinction
is, perhaps, somewhat academic [8]. We have previously observed
that substantial sample sizes, probably in excess of 1000 for
carotid-femoral PWV and higher for brachial-ankle PWV, are
required before cross-sectional associations with an IAD can be
reliably demonstrated [9]. Thus, the numbers examined by
Nolde et al. may have been underpowered in their ability to
demonstrate a true relationship, and restriction to dichotomous
rather than continuous analysis may have further compounded
this [10].
The cohort studied were drawn from a tertiary hospital
hypertension clinic, whereas the INTERPRESS-IPD population
included 56% with hypertension and selected clinical cohorts
were not eligible for inclusion [2]. It is likely, therefore, that Nolde
et al.’s failure to show the previously described association of
magnitude of IAD with absolute BP could also be attributed to the
restricted range of baseline BPs within their cohort [1–3, 11].
Whilst we have compelling data to show how detection of an
IAD can be applied to refine risk assessment for primary
prevention of events, thus informing individual treatment
decisions, this association does not always hold true for people
at higher risk. Magnitude of IAD has been correlated with severity
of coronary artery disease as assessed by Gensini or SYNTAX
scores in small studies (n= 104 and 106) of people presenting for
angiography [12, 13]. In contrast, the much larger prospective
SMART study of 7344 participants followed over a median of 5.9
years associated increasing systolic IAD with increased risks of
vascular events in people without, but not with, pre-existing
vascular disease after carefully adjusted analyses [14]. This
highlights the point that cross-sectional associations of IAD with
markers of cardiovascular risk cannot be assumed to translate
directly into higher prospective risks of events. There will be
degrees of residual confounding to account for; attendees for
coronary arteriography or tertiary management of hypertension
will already be classified as possessing high cardiovascular risk by
any measure. Consequently, they should all be receiving
interventions to lower BP and lipids without recourse to
assessment of surrogate markers of risk. Risk stratification of
higher-risk groups, whilst a perfectly valid research question, does
not, therefore, carry the same potential to inform clinical
management decisions as our findings for the INTERPRESS-IPD
population [2].
Data held in the INTERPRESS-IPD Collaboration are largely
derived from sequential blood pressure measurements [2]. As
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Nolde et al. correctly observe, the magnitude of such IAD
measurements is greater than comparable simultaneous measure-
ments [1, 3, 15]. In their study, they used the Microlife Watch BP
Office device – a two cuff device capable of repeated
simultaneous measures, although they only obtained a single
pair of measurements for their study. This might account for the
high (16.6%) prevalence of systolic IAD ≥ 10mmHg that was found
in this cohort, compared to our previously reported pooled
prevalence of 11.2% (95% confidence interval [CI]= 9.1–13.6) in
hypertension based on repeated simultaneous measurements
from seven studies; repeated measures are associated with falling
prevalences of IAD [1, 16]. Differences between IAD according to
method of measurement can be attributed to common causes of
BP variation such as order effects, white coat effects, and
regression to the mean [16]. Such variation can be attenuated
by controlled, repeated simultaneous measurement as is often
adopted in research studies [11]. It is unfortunate that the
opportunity for repeated measures offered by the Watch BP Office
device was not taken, in order to improve accuracy of reported
IADs. In considering sequential and simultaneous approaches,
sequential BP measurement has a high negative predictive value
for a simultaneous IAD, in other words, sequential measurement,
despite its inherent inaccuracies, can reliably rule out an IAD
where no significant IAD exists on simultaneous assessment [17].
Simultaneous measurement of BP in both arms requires the use of
either two devices together, which will approximate to simulta-
neously measured data, or a single two cuff (or four limb) device.
In primary care practitioners rarely have access to equipment that
can measure both arms simultaneously, and they need a practical
and simple method of assessment [18, 19]. Despite universal
hypertension guideline advice to measure both arms when
assessing people for hypertension, this at best appears to occur
in about 50% of cases [19]. So, for practical reasons, an
understanding of sequentially detected IADs is necessary since
this is highly likely to be method of measurement adopted in
primary care. Importantly, findings from both the INTERPRESS-IPD
Collaboration and other sequentially measured cohorts consis-
tently demonstrate the associations of IAD with all-cause
mortality, cardiovascular mortality and cardiovascular events
[2, 5, 20]. Thus experimental error in detection of IAD by
sequential measurement may produce higher absolute IADs than
repeated simultaneous assessment but is unlikely, in itself, to
sufficiently explain associations with mortality and cardiovascular
events.
In summary, Nolde et al.’s findings do not challenge the
importance of including IAD in assessment of cardiovascular risk
for primary prevention of future cardiovascular events and death.
This paper does emphasise that selected higher-risk populations
differ from those representative of the wider population. Risk
stratification is arguably of less importance when all interventions
that can reduce cardiovascular risk are already justified by pre-
existing medical history. Importantly, the contrast in sample sizes
is relevant and future studies of IAD can only be meaningful if they
are adequately powered.
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